 RAB10,1
 lung cancer,396
 Lung cancer,247
 non-small cell lung cancer,165
 NSCLC,134
NSCLC,126
 Lungs,117
Cancer,116
 Non-small cell lung cancer,109
 prognosis,97
 metastasis,86
Lung cancer,81
 Medical imaging,74
 cancer,74
 Cancer,68
 Radiation therapy,67
EGFR,56
 Metastasis,56
 immunotherapy,55
 Computed tomography,52
 Dosimetry,50
 Survival,50
 meta-analysis,48
 Prognosis,48
 chemotherapy,47
 lung adenocarcinoma,46
 apoptosis,45
 non-small-cell lung cancer,44
 survival,44
PubChem CID,42
Apoptosis,39
 non-small cell lung cancer ,37
 Immunotherapy,37
 Radiotherapy,37
 Surgery,36
 EGFR,33
 Medical treatment planning,32
 Lung,32
 PD-L1,32
 lung,30
 Lung neoplasms,29
ALK,29
 immunohistochemistry,29
 breast cancer,28
 overall survival,28
 Lung adenocarcinoma,27
 Apoptosis,26
 Non-small-cell lung cancer,26
 targeted therapy,25
Breast cancer,25
 Mesothelioma,25
 proliferation,24
 small cell lung cancer,24
 Image registration,24
 Radiation treatment,24
cancer,24
VATS,24
Chemotherapy,24
 EMT,22
 radiotherapy,22
 erlotinib,22
 microRNA,22
 nivolumab,21
 inflammation,21
 smoking,21
 mortality,20
Anatomy,20
Adenocarcinoma,20
Biomarker,20
 p53,19
 cisplatin,19
 Therapeutics,19
 biomarker,19
 Small cell lung cancer,19
 surgery,19
 Meta-analysis,18
 epidermal growth factor receptor,18
EMT,18
PD-L1,18
 drug resistance,18
 Smoking,18
 Targeted therapy,17
 Intensity modulated radiation therapy,17
 Drug delivery,17
Carcinoma,17
Non-small cell lung cancer ,17
EGFR mutation,17
 lobectomy,17
 invasion,17
 migration,16
 autophagy,16
 pemetrexed,16
 colorectal cancer,16
 oncology,16
 tyrosine kinase inhibitors,16
biomarker,16
 Immunohistochemistry,16
 KRAS,16
 gefitinib,16
 Positron emission tomography,16
 angiogenesis,16
lung cancer,16
Non-small cell lung cancer,15
 Epidemiology,15
 Erlotinib,15
 stereotactic radiosurgery,15
 Cone beam computed tomography,15
 reactive oxygen species,15
 Epidermal growth factor receptor,15
 quality of life,15
 Non-small cell lung cancer ,15
 ROS,15
PD-1,14
 cell cycle,14
 PET/CT,14
 Liver,14
 Migration,14
 Cytotoxicity,14
 Tissues,14
 mutation,14
Angiogenesis,14
 cytotoxicity,14
 brain metastasis,14
 Inflammation,14
 liquid biopsy,14
 lung neoplasms,14
 resistance,14
 paclitaxel,13
 squamous cell carcinoma,13
 Heart,13
 miRNA,13
 brain metastases,13
 Mortality,13
 pembrolizumab,13
Asbestos,13
 EGFR mutation,13
 mesothelioma,13
 pancreatic cancer,13
 melanoma,12
 cell proliferation,12
 Breast cancer,12
 chemoresistance,12
Non-small-cell lung cancer,12
 radiation therapy,12
 lymph node metastasis,12
Colorectal cancer,12
 diagnosis,12
 Autophagy,12
 Invasion,12
 thoracic surgery,12
 recurrence,11
Bronchoscopy,11
adenocarcinoma,11
 biomarkers,11
apoptosis,11
 vascular endothelial growth factor,11
Immunotherapy,11
 tumor microenvironment,11
 tyrosine kinase inhibitor,11
 STAT3,11
Brain metastasis,11
 osimertinib,11
Lung adenocarcinoma,11
KRAS,11
Bevacizumab,11
 Crizotinib,11
 Drug resistance,11
 Lung metastasis,11
 SCLC,10
 Reactive oxygen species,10
 Monte Carlo methods,10
 adenocarcinoma,10
 Prostate cancer,10
A549 cells,10
 Interstitial lung disease,10
 epithelial-mesenchymal transition,10
 treatment,10
 Toxicity,10
Brain metastases,10
 Neoplasm metastasis,10
 carcinoma,10
CT,10
 Screening,10
breast cancer,10
 Nanoparticles,10
 docetaxel,10
 Chemotherapy,10
 prostate cancer,10
 bevacizumab,10
SCLC,10
COPD,10
 PTEN,10
Biomarkers,10
 Diagnosis,10
 T790M,10
 Oxidative stress,10
AKT,9
 Medical image reconstruction,9
PET,9
 Metastases,9
